PDX: Moving beyond drug screening to versatile models for research discovery

Research output: Contribution to journalReview ArticleResearchpeer-review

17 Citations (Scopus)


Patient-derived xenografts (PDXs) are tools of the trade for many researchers from all disciplines and medical specialties. Most endocrinologists, and especially those working in oncology, commonly use PDXs for preclinical drug testing and development, and over the last decade large collections of PDXs have emerged across all tumor streams. In this review, we examine how the field has evolved to include PDXs as versatile resources for research discoveries, providing evidence for guidelines and changes in clinical practice.

Original languageEnglish
Article numberbvaa132
Number of pages9
JournalJournal of the Endocrine Society
Issue number11
Publication statusPublished - 1 Nov 2020


  • Breast cancer
  • Organoid
  • Pathology
  • Patient-derived xenograft
  • Preclinical testing
  • Prostate cancer

Cite this